License covers research from the University of Pittsburgh.

 Optherion licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for age-related macular degeneration (AMD) associated with specific variations in genes on Chromosome 10.

In 2005, scientists at the University of Pittsburgh published research in the American Journal of Human Genetics  showing a link between Chromosome 10, specifically the LOC387715 and HTRA1 genes, and AMD.

“The licensing agreement with the University of Pittsburgh adds significantly to our portfolio,” says Colin J. Foster, president and CEO of Optherion. “Optherion is now in a position to develop diagnostic tests based upon the most recently discovered genetic associations of dry AMD. We are optimistic that the innovative discoveries we are licensing will lead to diagnostic tests that can help change the current paradigm of AMD risk assessment and patient care.”

Previous articleGSK Awards Tolerx $70M Upfront for Access to mAb
Next articleNoven’s Stavzor Closer to Being Commercialized with Receipt of FDA Approvable Letter